Don't forget the words of a patient who *knows* th
Post# of 148288
(Total Views: 775)
Posted On: 07/02/2020 2:16:31 PM
Don't forget the words of a patient who *knows* they took Leronlimab: “The only way I can explain it is, it was like it felt like I had 1,000 cups of coffee,” said Recknor. “And then after the medicine, it was like a relaxing time on the beach. A couple days after the medicine, I was back to doing everything normal. I knew there were other people like me having crazy symptoms.
https://www.ajc.com/lifestyles/health/for-som...limab.news
And there is a world of hell out there in hospitals right now:
https://twitter.com/SuzeQKnits/status/1278724...11296?s=20 (please do not spam this woman about the drug - I'll be in touch directly with her the minute she can get access for her patients)
We know the country and the world needs a therapeutic badly. We know that Leronlimab saved the lives of four patients on the brink of death. We know the anecdotal evidence in iEND patients is that this drug does EXACTLY what the team has suspected. We know that the team is confident based on what they know so far. Everyone is working as quickly as they can to collate results while talking with BP and running other trials.
Please try to remember this as we go into the evening and tomorrow.
p.s. The target uses for Leronlimab:
ALLERGIES (ANAPHYLACTIC SHOCK) + ALZHEIMER'S + ASTHMA + ATHEROSCLEROSIS + ATOPIC DERMATITIS + CANCER + CELIAC DISEASE + CHRONIC FATIGUE SYNDROME + CHRONIC KIDNEY DISEASE (UNDERLYING PATHOLOGIES) + COPD + COVID-19 (AND OTHER CORONAVIRUSES) + CROHN'S DISEASE + COLITIS + COVID-RELATED PEDIATRIC INFLAMMATORY SYNDROME + DERMATOMYOSITIS + DIABETES (TYPE 1 AND 2) + DUCHENNE MUSCULAR DYSTROPHY (POSSIBLY OTHER MUSCULAR DYSTROPHIES ALSO) + EMPHYSEMA + FIBROMYALGIA + GRAVE’S DISEASE + GUILLAIN-BARRE SYNDROME + GVHD + HASHIMOTO’S THYROIDITIS + HEPATITIS (AUTOIMMUNE) + HIV + IDIOPATHIC PULMONARY FIBROSIS + INFLAMMATORY BOWEL DISEASE + INFLUENZA (SEVERE) + KAWASAKI SYNDROME + LAMBERT-EATON SYNDROME + LUPUS + MARSHALL’S SYNDROME (PFAPA) + MULTIPLE SCLEROSIS + MYASTHENIA GRAVIS + MYOCARDITIS + NASH + NEUROFIBROMATOSIS + PARKINSON'S DISEASE + PEMPHIGUS + PNEUMONIA + POLYMYOSITIS + POST-COVID SYNDROME + POST-MYOCARDIAL INFARCTION SYNDROME + PSORIASIS + RHEUMATIC FEVER + RHEUMATOID ARTHRITIS + SARCOIDOSIS + SCLERODERMA + SICKLE CELL DISEASE (ANTI-INFLAMMATORY EFFECT) + SJOGREN’S SYNDROME + STROKE + TUBERCULOSIS + VASCULITIS
https://www.ajc.com/lifestyles/health/for-som...limab.news
And there is a world of hell out there in hospitals right now:
https://twitter.com/SuzeQKnits/status/1278724...11296?s=20 (please do not spam this woman about the drug - I'll be in touch directly with her the minute she can get access for her patients)
We know the country and the world needs a therapeutic badly. We know that Leronlimab saved the lives of four patients on the brink of death. We know the anecdotal evidence in iEND patients is that this drug does EXACTLY what the team has suspected. We know that the team is confident based on what they know so far. Everyone is working as quickly as they can to collate results while talking with BP and running other trials.
Please try to remember this as we go into the evening and tomorrow.
p.s. The target uses for Leronlimab:
ALLERGIES (ANAPHYLACTIC SHOCK) + ALZHEIMER'S + ASTHMA + ATHEROSCLEROSIS + ATOPIC DERMATITIS + CANCER + CELIAC DISEASE + CHRONIC FATIGUE SYNDROME + CHRONIC KIDNEY DISEASE (UNDERLYING PATHOLOGIES) + COPD + COVID-19 (AND OTHER CORONAVIRUSES) + CROHN'S DISEASE + COLITIS + COVID-RELATED PEDIATRIC INFLAMMATORY SYNDROME + DERMATOMYOSITIS + DIABETES (TYPE 1 AND 2) + DUCHENNE MUSCULAR DYSTROPHY (POSSIBLY OTHER MUSCULAR DYSTROPHIES ALSO) + EMPHYSEMA + FIBROMYALGIA + GRAVE’S DISEASE + GUILLAIN-BARRE SYNDROME + GVHD + HASHIMOTO’S THYROIDITIS + HEPATITIS (AUTOIMMUNE) + HIV + IDIOPATHIC PULMONARY FIBROSIS + INFLAMMATORY BOWEL DISEASE + INFLUENZA (SEVERE) + KAWASAKI SYNDROME + LAMBERT-EATON SYNDROME + LUPUS + MARSHALL’S SYNDROME (PFAPA) + MULTIPLE SCLEROSIS + MYASTHENIA GRAVIS + MYOCARDITIS + NASH + NEUROFIBROMATOSIS + PARKINSON'S DISEASE + PEMPHIGUS + PNEUMONIA + POLYMYOSITIS + POST-COVID SYNDROME + POST-MYOCARDIAL INFARCTION SYNDROME + PSORIASIS + RHEUMATIC FEVER + RHEUMATOID ARTHRITIS + SARCOIDOSIS + SCLERODERMA + SICKLE CELL DISEASE (ANTI-INFLAMMATORY EFFECT) + SJOGREN’S SYNDROME + STROKE + TUBERCULOSIS + VASCULITIS
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼